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The total synthesis of the plant natural product altissimacoumarin D was achieved 
by the Mitsunobu alkylation of isofraxidin by geraniol. Isofraxidin was prepared from 
2,4-dihydroxybenzaldehyde in five steps. The key reaction was the Knoevenagel condensation of 
an ortho-hydroxybenzaldehyde with Meldrum’s acid under neutral conditions in water and one-pot 
acid catalyzed cyclization to the coumarin.
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Introduction
Historically, natural products are a rich source of 
biologically active compounds including many of our current 
therapeutic agents.1-5 In the present day, natural products 
continue to play a significant role in the development of small 
molecule chemical probes for the new science of epigenetics.6 
Numerous natural products that inhibit specific epigenetic 
enzyme-catalyzed structural modifications of nucleic acids 
and histone proteins are known, such as laccaic acid (targeting 
deoxyribonucleic acid (DNA) methyltransferase),7 anacardic 
acid (targeting histone acetyltransferase),8 trichostatin A 
(targeting histone deacetylase),9 nauhoic acid (targeting 
lysine methyltransferase)10 and tripartin (targeting lysine 
demethylase).11 The depsipeptide romidepsin, a histone 
deacetylase inhibitor of bacterial origin, is a particularly 
impressive case as it has progressed from discovery to 
an approved epigenetic drug for the treatment of T-cell 
lymphoma.12,13
The zinc-dependent histone deacetylases (HDACs) are 
enzymes that hydrolyze acyl-lysine (chiefly acetyl-lysine) 
residues in proteins and revert them to native lysine, usually 
with a gene silencing effect as a consequence.14 An additional 
class of sirtuin histone deacylases catalyze the same 
reaction through an entirely different nicotinamide adenine 
dinucleotide (NAD+)-dependent catalytic mechanism. The 
seven human sirtuins, Sirt1-7, are implicated in a number 
of disease conditions and there is much interest in both 
activators and inhibitors of sirtuin enzymes.15 Although some 
dietary natural products such as resveratrol, quercetin or 
epigallocatechin gallate are reported as sirtuin modulators, 
their promiscuous nature is non-ideal for use as chemical 
probes and more selective molecules are needed. A recent 
lead from natural product screening comes from Ailanthus 
altissima (the tree of heaven), a plant used in Chinese 
and Korean traditional medicine. From the bark extract, 
four coumarins were identified that are Sirt1 activators 
(Figure 1).16 At a concentration of 10 µM, the most active 
compound altissimacoumarin D significantly increased Sirt1 
catalyzed deacetylation of a p53 peptide Sirt1 substrate 
in vitro and decreased the transcriptional activity of p53 in 
a cell-based reporter assay.
Due to the interesting biological activity, we embarked 
on the total synthesis of altissimacoumarin D. Our biogenetic 
retrosynthesis (Figure 2) assumed that the likely origin of 
altissimacoumarin D (1) is through the geranylation of 
another coumarin natural product, isofraxidin (2). There 
are several total syntheses of isofraxidin in the literature, 
by Spath and Jerzmanowska-Sienkiewiczowa,17 Spath 
and Dobrovolny,18 Rouessac and Leclerc,19 Chen20 and 
Gao et al.21 from which we selected the Chen route as the 
starting point for our studies due to its concise and simple 
nature. In Chen’s four step synthesis, isofraxidin arose 
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from the formation of a coumarin from an o-hydroxy 
benzaldehyde derivative, which is in turn prepared by 
the functionalization of resorcinol. Nevertheless, we 
have substantially altered the reaction conditions for the 
Knoevenagel reaction and subsequent coumarin cyclization 
compared to the published procedure.
Results and Discussion
Our synthesis began with the halogenation of 
commercially available 2,4-dihydroxybenzaldehyde 
(3, Scheme 1) to give the dibrominated derivative 4. 
Halogen displacement under van Koten’s conditions 
with copper(I) chloride and sodium methoxide afforded 
2,4-dihydroxy-3,5-dimethoxybenzaldehyde (5) in good 
yield.22 At this stage, Chen’s Knoevenagel condensation 
with diethyl malonate was attempted but resulted in poor 
yields. Furthermore, the lack of experimental detail made 
an effective reproduction difficult. The method used 
in Rouessac’s synthesis,19 whereby a trimethoxylated 
benzaldehyde was condensed with Meldrum’s acid and 
zinc oxide, was also unsatisfactory when applied to 
our aldehyde 5. After investigating alternative reaction 
conditions, we achieved a high yield of the Knoevenagel 
adduct 6 with Bigi’s procedure.23 This mild protocol with 
Meldrum’s acid in the absence of extraneous acid or base 
catalysis has the benefit of being environmentally green 
as it is conducted in water without organic co-solvents. 
While intermediate 6 was cyclized to coumarin 7 in 90% 
yield under acid catalysis, we discovered that telescoping 
the Knoevenagel condensation and cyclization in a one-
pot operation from aldehyde 5 to coumarin 7 was more 
efficient. The final step in the isofraxidin synthesis was the 
coumarin decarboxylation, for which our best yields were 
obtained by refluxing 7 in pyridine and ethylene glycol.24 
With isofraxidin in hand through a five step sequence 
(58% overall yield), we introduced the geranyl sidechain. 
Under Mitsunobu conditions at room temperature, the 
reaction between isofraxidin and geraniol (Scheme 2) 
provided altissimacoumarin D (1). Although the reaction 
proceeded in a modest 54% yield, there was no attempt at 
optimization as we obtained a sufficient quantity (100 mg) 
of the natural product for biological studies. Our synthetic 
material had an excellent match with the 1H and 13C nuclear 
magnetic resonance (NMR) spectroscopic data reported for 
the natural product (Table 1).
Figure 1. The structures of altissimacoumarin Sirt1 activators.
Figure 2. Retrosynthesis of altissimacoumarin D (1) from resorcinol.
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Conclusions
In summary, we report the total synthesis of the 
Sirt1 activator altissimacoumarin D in six steps from 
2,4-dihydroxybenzaldehyde. A noteworthy feature is 
the new high-yielding route towards the intermediary 
isofraxidin via Knoevenagel condensation in water 
followed by cyclization to the coumarin carboxylic acid 7 
in one-pot. Thermal decomposition of the pyridinium salt 
of 7 effected decarboxylation to give isofraxidin in high 
yield, after which geranylation afforded altissimacoumarin 
D. The ready access to altissimacoumarin D will facilitate 
its use as a starting material for the synthesis of the more 
heavily oxygenated natural products in this family, while 
the modular route facilitates the synthesis of analogues for 
structure-activity relationship studies.
Experimental
2,4-Dihydroxybenzaldehyde was obtained commercially 
(Sigma-Aldrich Co., St. Louis, MO, USA) and used 
without further purification. All reactions involving a 
dry atmosphere were performed with a slight positive 
pressure of argon. Analytical thin-layer chromatography 
Scheme 1. (a) Br2, EtOH, 30 min (98%); (b) NaOMe, CuCl, MeOH/DMF, reflux, 4 h (70%); (c) Meldrum’s acid, H2O, 80 ºC, 2 h, (94%); (d) H2SO4, 
90 min (90%); (e) one-pot combination of (c) and (d) (90%); (f) Py, ethylene glycol, reflux, 3.5 h (94%). 
Scheme 2. (a) Geraniol, Ph3P, diisopropyl azodicarboxylate (DIAD), tetrahydrofuran (THF), 24 h (54%).
Table 1. Comparison of altissimacoumarin D 1H and 13C NMR chemical 
shifts between the naturally isolated material and the synthetic sample





1.59 (s) 1.52 (s) 16.4 16.4
1.67 (s) 1.60 (s) 17.6 17.6
1.69 (s) 1.63 (s) 25.6 25.6
2.05, 2.08 (m) 1.99 (m) 26.3 26.3
3.89 (s) 3.82 (s) 39.6 39.6
4.03 (s) 3.96 (s) 56.3 56.2
4.68 (d, J 7 Hz) 4.62 (d, J 7 Hz) 61.7 61.7
5.06 (t, J 7 Hz) 5.00 (t, J 8 Hz) 70.3 70.2
5.56 (t, J 7 Hz) 5.49 (t, J 8 Hz) 103.5 103.5
6.34 (d, J 10 Hz) 6.28 (d, J 8 Hz) 114.4 114.4
6.66 (s) 6.58 (s) 115.1 115.1
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was done on 0.25 mm silica gel 60 F254 plates, and 
compounds visualized using UV irradiation or KMnO4. 
Flash chromatography was carried out on columns packed 
with silica gel 60 (0.040-0.063 mm particle sizes). Nuclear 
magnetic resonance (NMR) spectra were obtained on a 
Bruker Avance-III spectrometer. The splitting patterns are 
reported as s (singlet), d (doublet), t (triplet), q (quartet), 
and m (multiplet). 
3,5-Dibromo-2,4-dihydroxybenzaldehyde (4, CAS 
116096-91-4)
To a stirred solution of 2,4-dihydroxybenzaldehyde 
(2.8 g, 20 mmol) in ethanol (40 mL) was added bromine 
(6.4 g, 40 mmol) dropwise at room temperature. After 
stirring for 30 min the reaction mixture was poured into 
distilled water (100 mL) and filtered. The filtrate was 
washed with water and the residual bromine present in the 
aqueous phase was quenched with a saturated solution of 
sodium thiosulfate. Compound 4 was obtained as a white 
powder (5.9 g, 98%), and the physical and spectroscopic 
data are in accordance with those previously reported.25 
mp 188-189 ºC (Lit.25 mp 200 ºC); ¹H NMR (400 MHz, 
methanol-d4) d 7.88 (s, 1H), 9.71 (s, 1H); ¹³C NMR 
(100 MHz, methanol-d4) d 103.1, 119.9, 132.0, 138.5, 
154.1, 154.7, 196.2.
2,4-Dihydroxy-3,5-dimethoxybenzaldehyde (5, CAS 
182427-46-9)
To a stirred solution of 4 (11.8 g, 40 mmol) in 
a 2:5 solution of anhydrous methanol in anhydrous 
dimethylformamide (70 mL) was added CuCl (0.5 g, 
5 mmol) and NaOMe (21.6 g, 400 mmol). The reaction 
mixture was heated under reflux at 100 ºC for 4 h. The 
solvent was then evaporated in vacuo, distilled water 
(50 mL) was added and the pH adjusted to 2 using 
concentrated HCl. After 15 min the reaction mixture 
was transferred into a separation funnel and the product 
extracted using chloroform (5 × 20 mL). The organic 
layer was washed with brine, dried with MgSO4, filtered 
and the solvent evaporated in vacuo. Compound 5 was 
obtained as a brown solid (5.5 g, 70%), and the physical and 
spectroscopic data are in accordance with those previously 
reported.21 mp 88-89 ºC (Lit.21 mp 87.5-89.8 ºC); ¹H NMR 
(400 MHz, DMSO-d6) d 3.86 (s, 6H), 7.29 (s, 1H), 8.68 
(s, 1H); ¹³C NMR (100 MHz, CDCl3) d 56.6, 60.9, 109.0, 
112.9, 134.6, 141.3, 147.1, 151.7, 194.6.
5-(2,4-Dihydroxy-3,5-dimethoxybenzylidene)-2,2-dimethyl-
1,3-dioxane-4,6-dione (6)
Meldrum’s acid (0.16 g, 1 mmol) was added to a stirred 
solution of aldehyde 5 (0.210 g, 1 mmol) in 2 mL of water 
at 80 ºC and the reaction mixture left for 2 h to the point 
where a precipitate was formed. The solid was filtered and 
dried to give compound 6 as a white solid (0.323 g, 94%). 
mp 259-261 °C; ¹H NMR (400 MHz, MeOD-d1) d 2.05 
(s, 6H), 3.85 (s, 3H), 3.88 (s, 3H), 7.05 (s, 1H), 8.70 (s, 
1H); 13C NMR (100 MHz, MeOD-d1) d 56.2, 60.8, 105.8, 
109.5, 112.8, 134.2, 144.7, 145.9, 146.9, 149.6, 157.5, 
164.2 (some carbon signals are coincident). 
7-Hydroxy-6,8-dimethoxy-2-oxo-2H-chromene-3-carboxylic 
acid (7, CAS 149143-82-8)
Meldrum’s acid (0.16 g, 1 mmol) was added to a stirred 
solution of aldehyde 5 (0.210 g, 1 mmol) in 2 mL of water 
at 80 ºC. After two hours, the reaction mixture was cooled 
and acidified at 0 oC to pH 1 with concentrated sulfuric 
acid. After stirring for 1.5 h, the solution was poured 
onto crushed ice and warmed to room temperature. The 
crystals were filtered, washed with water, and dried to 
give coumarin 7 as white crystals (0.25 g, 90%), and the 
physical and spectroscopic data are in accordance with 
those previously reported.19 mp 227-228 ºC (Lit.19 mp 
227-228 ºC); ¹H NMR (400 MHz, DMSO-d6) d 3.84 (s, 
6H), 4.63 (br s, 2H), 7.26 (s, 1H), 8.66 (s, 1H); 13C NMR 
(100 MHz, DMSO-d6) d 56.2, 60.8, 105.9, 109.5, 112.8, 
134.2, 144.7, 145.9, 146.9, 149.6, 157.5, 164.2.
7-Hydroxy-6,8-dimethoxy-2H-chromen-2-one (2, isofraxidin, 
CAS 486-21-5)
Coumarin 7 (0.32 g, 1.4 mmol) was refluxed for 3.5 h in 
a solution of pyridine/ethylene glycol (1.35 mL/1.21 mL). 
The solution was cooled, acidified with 2 M HCl and 
extracted with dichloromethane. Solvent evaporation 
afforded isofraxidin (2) as white crystals (0.25 g, 94%), 
and the physical and spectroscopic data are in accordance 
with those previously reported.19 mp 148-149 ºC (Lit.19 
mp 144 ºC); ¹H NMR (400 MHz, CDCl3) d 3.86 (s, 3H), 
4.01 (s,3H), 6.21 (d, J 9.0 Hz, 1H), 6.59 (s, 1H), 7.54 (d, 
J 9.0 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) d 56.2, 
60.8, 105.9, 109.5,112.8, 134.2, 144.5, 145.9, 146.9, 
149.6, 164.2.
Altissimacoumarin D (1, CAS 1388627-67-5)
To a stirring solution of isofraxidin (0.110 g, 0.31 mmol) 
in anhydrous tetrahydrofuran (THF, 1.0 mL) was added 
triphenylphosphine (0.081 g, 0.31 mmol) and geraniol 
(0.05 mL, 0.29 mmol). DIAD (0.05 g, 0.25 mmol) in THF 
(0.5 mL) was added dropwise and the reaction mixture 
left stirring for 24 hours. The solvent was removed and 
the crude product purified by preparative thin layer 
chromatography with an eluent of 6% MeOH/CH2Cl2. 
The product was extracted from the silica with a solution 
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of 10% MeOH/CH2Cl2, filtered and the solvent evaporated 
in vacuo to afford altissimacoumarin D as a colourless 
solid (0.10 g, 54%); mp 225-226 ºC; ¹H NMR (400 MHz, 
CDCl3) d 1.52 (s, 3H), 1.60 (s, 3H), 1.63 (s, 3H), 1.99 (m, 
4H), 3.82 (s, 3H), 3.96 (s, 3H), 4.62 (d, J 7 Hz, 2H), 5.00 
(t, J 8 Hz, 1H), 5.49 (t, J 8 Hz, 1H), 6.28 (d, J 8 Hz, 1H), 
6.58 (s, 1H), 7.54 (d, J 12 Hz); 13C NMR (100 MHz, CDCl3) 
d 16.4, 17.6, 25.6, 26.3, 39.6, 56.2, 61.7, 70.2, 103.5, 114.4, 
115.1, 119.6, 123.8, 131.7, 141.8, 142.5, 143.0, 143.4, 
144.9, 150.7, 160.5.
Supplementary Information
Supplementary information (1H and 13C NMR spectra) 
is available free of charge at http://jbcs.org.br as a PDF file.
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